158 related articles for article (PubMed ID: 17109471)
1. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
Wu W; Weigand L; Belkaid Y; Mendez S
Eur J Immunol; 2006 Dec; 36(12):3238-47. PubMed ID: 17109471
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
3. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.
Mendez S; Tabbara K; Belkaid Y; Bertholet S; Verthelyi D; Klinman D; Seder RA; Sacks DL
Infect Immun; 2003 Sep; 71(9):5121-9. PubMed ID: 12933855
[TBL] [Abstract][Full Text] [Related]
4. The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides.
Wu W; Weigand L; Mendez S
Can J Microbiol; 2009 Jun; 55(6):705-13. PubMed ID: 19767842
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
6. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis.
Okwor I; Liu D; Uzonna J
Vaccine; 2009 Apr; 27(19):2554-62. PubMed ID: 19428861
[TBL] [Abstract][Full Text] [Related]
7. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
[TBL] [Abstract][Full Text] [Related]
8. The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB/c mice.
Alavizadeh SH; Badiee A; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Jaafari MR
Exp Parasitol; 2012 Nov; 132(3):313-9. PubMed ID: 22819791
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
Shah JA; Darrah PA; Ambrozak DR; Turon TN; Mendez S; Kirman J; Wu CY; Glaichenhaus N; Seder RA
J Exp Med; 2003 Jul; 198(2):281-91. PubMed ID: 12874261
[TBL] [Abstract][Full Text] [Related]
10. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
11. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.
Ahmed SB; Bahloul C; Robbana C; Askri S; Dellagi K
Vaccine; 2004 Apr; 22(13-14):1631-9. PubMed ID: 15068845
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice.
Iborra S; Parody N; Abánades DR; Bonay P; Prates D; Novais FO; Barral-Netto M; Alonso C; Soto M
Microbes Infect; 2008; 10(10-11):1133-41. PubMed ID: 18603012
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Leishmanization Using
Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
Front Immunol; 2020; 11():1725. PubMed ID: 33193290
[No Abstract] [Full Text] [Related]
14. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
15. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice.
Wu W; Huang L; Mendez S
Eur J Immunol; 2010 Sep; 40(9):2517-27. PubMed ID: 20683901
[TBL] [Abstract][Full Text] [Related]
16. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
17. Progress towards a Leishmania vaccine.
Tabbara KS
Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
[TBL] [Abstract][Full Text] [Related]
19. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.
Scott P; Artis D; Uzonna J; Zaph C
Immunol Rev; 2004 Oct; 201():318-38. PubMed ID: 15361250
[TBL] [Abstract][Full Text] [Related]
20. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis.
Liese J; Schleicher U; Bogdan C
Eur J Immunol; 2007 Dec; 37(12):3424-34. PubMed ID: 18034422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
